Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer.
Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer.
复制标题
DOI：
10.3346/jkms.2010.25.6.846
复制
发表时间：
2010-06
影响因子：
4.5
通讯作者：
Liang J
中科院分区：
文献类型：
--
作者：
Li QF;Yao RY;Liu KW;Lv HY;Jiang T;Liang J
本研究旨在评价谷胱甘肽S转移酶P1Ile105Val基因多态性对奥沙利铂/5-氟尿嘧啶为主的晚期胃癌化疗的预测价值。对以奥沙利铂/5-FU为主的一线化疗方案治疗的晚期胃癌患者进行观察。用TaqMan-MGB探针等位基因鉴别法检测GSTP1 Ile105Val基因多态性。用疾病控制率评价治疗反应。记录进展时间、总生存期和毒性反应。GSTP1等位基因频率分别为105Ile/105Ile 52%、105Ile/105Val 41%和105Val/105Val 7%。105Ile/105Ile和至少一个105Val等位基因携带者的疾病控制率分别为39%和71%(P=0.026)，中位进展时间分别为4.0月和7.0月(P=0.002)，中位生存期分别为7.0月和9.5月(P=0.002)。两个105Ile等位基因携带者的神经毒性发生率较高(P=0.005)。总之，至少有一个105Val等位基因的患者对以奥沙利铂/5-FU为基础的一线方案作为一线治疗进展期胃癌患者的预后和疗效更好。
The aim of this study was to evaluate the predictive value of the polymorphism Glutathione S-transferase P1 (GSTP1) Ile105Val on oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. Patients with advanced gastric cancer accepted oxaliplatin/5-FU-based chemotherapy as first-line chemotherapy were investigated. GSTP1 Ile105Val polymorphism was detected by TaqMan-MGB probe allelic discrimination method. Response to treatment was assessed by disease controlled rate. Time to progression, overall survival and toxicities were recorded. Final patient outcomes were as follows: the allele frequencies of GSTP1 were 105Ile/105Ile 52%, 105Ile/105Val 41% and 105Val/105Val 7%. For patients with 105Ile/105Ile and those with at least one 105Val allele, disease control rate was 39% and 71% (P=0.026), respectively; median time to progression was 4.0 and 7.0 months (P=0.002); median overall survival time was 7.0 and 9.5 months (P=0.002). Neurological toxicity was more frequently occurred in patients with two 105Ile alleles (P=0.005). In conclusion, patients with at least one 105Val allele have better prognosis and response to oxaliplatin/5-FU-based regimen as first-line treatment for patients with advanced gastric cancer.
登录
查看更多内容
影响因子：
8.8
作者：
通讯作者：
--
影响因子：
3.9
作者：
Srivastava, SK;Singhal, SS;Singh, SV
通讯作者：
Singh, SV
影响因子：
6.4
作者：
Cabelguenne, A;Loriot, MA;De Waziers, I
通讯作者：
De Waziers, I
DOI：
10.1097/00008571-200210000-00006
发表时间：
2002-10-01
期刊：
PHARMACOGENETICS
影响因子：
--
作者：
Ishimoto, TM;Ali-Osman, F
通讯作者：
Ali-Osman, F
影响因子：
4.7
作者：
Watson, MA;Stewart, RK;Bell, DA
通讯作者：
Bell, DA